Основная статистика
| LEI | 549300XV44Q9Z1MIPQ03 |
| CIK | 1582313 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Xenon Pharmaceuticals Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 11, 2025 |
Exhibit 99.1 Xenon Reports Second Quarter 2025 Financial Results & Business Update – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated – Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHAR |
|
| August 11, 2025 |
Employment Agreement, dated June 2, 2025, by and between the Company and Darren Cline. Exhibit 10.2 June 2, 2025 CONFIDENTIAL Via Electronic Mail Darren Cline Dear Darren, Re: Offer of Employment We are pleased to offer you a position with Xenon Pharmaceuticals USA Inc. (the “Company”), a wholly-owned subsidiary of Xenon Pharmaceuticals Inc. (the “Parent”), as Chief Commercial Officer, commencing on or about June 23, 2025. Subject to Sections L through P below, the Company agrees to |
|
| August 11, 2025 |
Form of Restricted Share Unit Award Agreement. Exhibit 10.1 RESTRICTED SHARE UNIT AWARD AGREEMENT (NON-EMPLOYEE DIRECTORS) THIS AGREEMENT made on [] (the “Date of Grant”) AMONG: Xenon Pharmaceuticals Inc., a company incorporated under the laws of Canada (the “Company”) AND: [First Name, Last Name, Title] (the “Grantee”) WHEREAS: A. The Grantee is a director, officer, employee or Consultant of the Company or of a subsidiary of the Company or of |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHA |
|
| May 12, 2025 |
Form of Performance Share Unit Award Agreement. Exhibit 10.6 PERFORMANCE SHARE AWARD AGREEMENT THIS AGREEMENT made on [] (the “Date of Grant”) AMONG: Xenon Pharmaceuticals Inc., a company incorporated under the laws of Canada (the “Company”) AND: [First Name, Last Name, Title] (the “Grantee”) WHEREAS: A. The Grantee is a director, officer, employee or Consultant of the Company or of a subsidiary of the Company or of an Affiliate of the Company |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2025 |
Form of Restricted Share Unit Award Agreement. Exhibit 10.5 RESTRICTED SHARE UNIT AWARD AGREEMENT THIS AGREEMENT made on [] (the “Date of Grant”) AMONG: Xenon Pharmaceuticals Inc., a company incorporated under the laws of Canada (the “Company”) AND: [First Name, Last Name, Title] (the “Grantee”) WHEREAS: A. The Grantee is a director, officer, employee or Consultant of the Company or of a subsidiary of the Company or of an Affiliate of the Comp |
|
| May 12, 2025 |
Exhibit 99.1 Xenon Reports First Quarter 2025 Financial Results and Provides Business Update – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner dru |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 17, 2025 |
March 14, 2025 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 5, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 5, 2025 |
Letter from KPMG LLP, dated March 3, 2025. March 3, 2025 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Xenon Pharmaceuticals Inc. (the Company) and, under the date of February 27, 2025, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2024 and 2023 and the effectiveness of internal control over financ |
|
| February 27, 2025 |
Exhibit 10.33 POST-EMPLOYMENT CONSULTING AGREEMENT This CONSULTING AGREEMENT (“Agreement”) shall be binding and effective as of the date of the last signature below (“Effective Date”), by and between Xenon Pharmaceuticals Inc. (“Company”), and Sherry Aulin (“Consultant”). WHEREAS, Consultant is currently an employee Company with a planned resignation date of June 30, 2025; and WHEREAS, Company des |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K p UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMAC |
|
| February 27, 2025 |
Letter Agreement, dated January 15, 2025, by and between the Company and Christopher Von Seggern. Exhibit 10.30 CONFIDENTIAL January 15, 2025 Christopher E. Von Seggern BY EMAIL Dear Chris: This letter is to summarize the terms of the separation package that Xenon Pharmaceuticals USA Inc., a wholly owned subsidiary of Xenon Pharmaceuticals Inc. (collectively, the “Company”), is willing to offer you. Please read this letter agreement (the “Letter Agreement”), which includes a general release, c |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Xenon Pharmaceuticals Inc. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 27, 2025 |
Exhibit 10.31 CONSULTING AGREEMENT This CONSULTING AGREEMENT (“Agreement”) is entered into as of January 17, 2025 (“Effective Date”), by and between Xenon Pharmaceuticals USA, Inc. (“Company”), and Christopher E. Von Seggern (“Consultant”). WHEREAS, Consultant has offered to provide certain consulting services (“Services”) to Company; and WHEREAS, Company desires to retain Consultant to provide su |
|
| February 27, 2025 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURTIIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Xenon Pharmaceuticals Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares, no par value per share. The general terms and provisions of our common shares are summarized below. This summary does |
|
| February 27, 2025 |
2025 Inducement Equity Incentive Plan and related form agreements. Exhibit 10.32 2025 INDUCEMENT EQUITY INCENTIVE PLAN XENON PHARMACEUTICALS INC. Article 1 Purpose 1.1 The purpose of this Plan is to promote the interests of Xenon Pharmaceuticals Inc. (the “Company”) by assisting the Company in attracting, retaining and motivating employees by providing an inducement material to individuals entering into employment with the Company or any of its subsidiaries. The |
|
| February 27, 2025 |
Exhibit 99.1 Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update – Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year – Phase 3 azetukalner bipolar depression program p |
|
| February 27, 2025 |
Exhibit 19 XENON PHARMACEUTICALS INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities TABLE OF CONTENTS Page I. INTRODUCTION 1 A. Persons Covered by this Policy 1 B. Legal Prohibitions on Insider Trading 1 C. Detection and Prosecution of Insider Trading 1 D. Penalties for Violation of Insider Trading Laws and this Policy 2 E. Compliance Officer 3 F. Reporti |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration Statement No. |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2024 |
Exhibit 99.1 Xenon Reports Q3 2024 Financial Results and Business Update – Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple c |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Xenon Pharmaceuticals, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
Xenon Reports Q2 2024 Financial Results and Business Update Exhibit 99.1 Xenon Reports Q2 2024 Financial Results and Business Update – Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 – MDD program on track with Phase 3 study expected to initiate in H2 2024 – Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHAR |
|
| June 5, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 5, 2024 |
As filed with the Securities and Exchange Commission on June 5, 2024 As filed with the Securities and Exchange Commission on June 5, 2024 Registration Statement No. |
|
| June 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Xenon Pharmaceuticals Inc. |
|
| June 5, 2024 |
Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder. Exhibit 10.1 AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN XENON PHARMACEUTICALS INC. (as amended effective June 4, 2024) Article 1 PURPOSE 1.1 The purpose of this Plan is to promote the interests of Xenon Pharmaceuticals Inc. (the “Company”) by: (a) furnishing certain directors, officers, employees of the Company and its subsidiaries or other persons as the Board of Directors may approve with g |
|
| May 9, 2024 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHA |
|
| May 9, 2024 |
Form of Performance Share Award Agreement FORM OF PERFORMANCE SHARE AWARD AGREEMENT THIS AGREEMENT made on [] (the “Date of Grant”) AMONG: Xenon Pharmaceuticals Inc. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 8, 2024 |
Exhibit 99.1 March 7, 2024 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders: Date of meeting: June 4, 2024 Record date for notice: April 5, 2024 Reco |
|
| March 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 29, 2024 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025 Planned “end-of-Phase |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 29, 2024 |
Exhibit 10.27 CONSENT TO ALTERATIONS AGREEMENT THIS AGREEMENT MADE EFFECTIVE AS OF AUGUST 16, 2023 BETWEEN REDSTONE ENTERPRISES LTD. (“Landlord”) AND XENON PHARMACEUTICALS INC. (“Tenant”) WHEREAS A. By a Lease Agreement dated November 24, 2021 (the “Original Lease”) between the Landlord and the Tenant, the Landlord demised unto the Tenant, for and during a period of Ten (10) years commencing on Ju |
|
| February 29, 2024 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURTIIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Xenon Pharmaceuticals Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares, no par value per share. The general terms and provisions of our common shares are summarized below. This summary does |
|
| February 29, 2024 |
Clawback Policy, effective as of October 2, 2023 Exhibit 97 XENON PHARMACEUTICALS INC. CLAWBACK POLICY As adopted on November 20, 2023 Xenon Pharmaceuticals Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this policy called the Clawback Policy (the “Policy”). The Policy is intended to further the Company’s pay-for-performance philosophy and t |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEU |
|
| February 29, 2024 |
Employment Agreement, dated December 15, 2023, by and between the Company and James Empfield. Exhibit 10.28 December 15, 2023 Confidential Via Electronic Mail James Empfield Dear James, Re: Third Amended and Restated Employment Agreement We are pleased to offer you this Third Amended and Restated Employment Agreement which replaces and supersedes your earlier Offers of Employment (the “Prior Agreements”) dated February 2016, January 1, 2017 and March 20, 2019 with Xenon Pharmaceuticals USA |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Xenon Pharmaceuticals, Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2024 |
XENE / Xenon Pharmaceuticals Inc. / DRIEHAUS CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 2 )* Xenon Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2023 (Date of Event Which R |
|
| February 8, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Xenon Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98420N105 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 30, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-260010 Prospectus supplement (To prospectus dated October 4, 2021) 8,461,542 Common shares Pre-funded warrants to purchase 769,230 common shares We are offering 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase 769,230 common shares in this offering. The purchase price of each pre-funded |
|
| November 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Xenon Pharmaceuticals Inc. |
|
| November 30, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 30, 2023 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [ ] (subject to adjustment) Original Issue Date: [ ], 2023 Warrant No. Xenon Pharmaceuticals Inc., a corporation continued under the federal laws of Canada (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns |
|
| November 30, 2023 |
Exhibit 1.1 8,461,542 Shares 769,230 Pre-funded Warrants Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENT November 29, 2023 J.P. MORGAN SECURITIES LLC JEFFERIES LLC BOFA SECURITIES, INC. STIFEL, NICOLAUS & COMPANY, INCORPORATED RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 c/o JEFFERIES LLC 520 Ma |
|
| November 29, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-260010 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| November 27, 2023 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD) Conference call today at 8:30 am ET VANCOUVER, British Columbia, November 27, 2023 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, do |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 9, 2023 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency VANCOUVER, British Columbia, November 9, 2023 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, ann |
|
| November 8, 2023 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder on track for late November to mid-December XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-cloni |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON |
|
| August 9, 2023 |
Exhibit 10.1 CONSENT TO ALTERATIONS AGREEMENT THIS AGREEMENT MADE EFFECTIVE AS OF MARCH 27, 2023 BETWEEN REDSTONE ENTERPRISES LTD. (“Landlord”) AND XENON PHARMACEUTICALS INC. (“Tenant”) WHEREAS A. By a Lease Agreement dated November 24, 2021 (the “Original Lease”) between the Landlord and the Tenant, the Landlord demised unto the Tenant, for and during a period of Ten (10) years commencing on July |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2023 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy programs including in X-TOLE2 and X-TOLE3 clinical trials in focal on |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q • UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PH |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2023 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover VANCOUVER, British Columbia, August 8, 2023 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover. Dr. Cann |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHA |
|
| May 9, 2023 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials Anticipate last patient to be screened next month in XEN1 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 14, 2023 |
Executive Incentive Compensation Plan. Exhibit 10.1 XENON PHARMACEUTICALS INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase shareholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1. “Actual Award” means as to any Performance Period, the actual award (if any) payab |
|
| March 8, 2023 |
Exhibit 99.1 March 8, 2023 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders: Date of meeting: June 1, 2023 Record date for notice: April 4, 2023 Reco |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 1, 2023 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expected in third quarter Conference call at 4:30 pm |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K o9kjoth.; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 1, 2023 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURTIIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Xenon Pharmaceuticals Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares, no par value per share. The general terms and provisions of our common shares are summarized below. This summary does |
|
| February 14, 2023 |
SC 13G/A 1 p23-0274sc13ga.htm XENON PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Xenon Pharmaceuticals, Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statem |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Xenon Pharmaceuticals Inc. (Title of Class |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 13)1 Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 98420N105 (CUSIP Number) Dece |
|
| February 10, 2023 |
XENE / Xenon Pharmaceuticals Inc / DRIEHAUS CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 schedule13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* Xenon Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, |
|
| November 8, 2022 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update XEN1101 Phase 3 program launched with initiation of X-TOLE2 clinical trial Strong financial position of approximately $752 million to fully support XEN1101 Phase 3 program development and expected cash runway into 2026 Conference call at 4:30 pm ET today BURNABY, British Colum |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 8, 2022 |
Employment Agreement, dated November 7, 2022, by and between the Company and Andrea DiFabio. Exhibit 10.1 November 4, 2022 CONFIDENTIAL Via Electronic Mail Andrea DiFabio Dear Andrea, Re: Offer of Employment We are pleased to offer you a position with Xenon Pharmaceuticals USA Inc. (the ?Company?), a wholly-owned subsidiary of Xenon Pharmaceuticals Inc. (the ?Parent?), as its Chief Legal Officer and Corporate Secretary, beginning on November 7, 2022 (the ?Start Date?). Subject to Sections |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON |
|
| November 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 7, 2022 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary BURNABY, British Columbia, November 7, 2022 ? Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHAR |
|
| August 9, 2022 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year Cash runway extended into 2026 following successful completion of equity offering in June Conference Call at 4:30 pm ET Today BURNABY, British Columbia, August 9, 2022 ? Xenon Pharm |
|
| August 9, 2022 |
Exhibit 10.1 CONSENT TO ALTERATIONS & LEASE MODIFICATION AGREEMENT THIS AGREEMENT MADE EFFECTIVE AS OF MAY 19, 2022 BETWEEN REDSTONE ENTERPRISES LTD. (?Landlord?) AND XENON PHARMACEUTICALS INC. (?Tenant?) WHEREAS A. By a Lease Agreement dated November 24, 2021 (the ?Lease?) between Landlord and Tenant, the Landlord demised unto the Tenant, for and during a period of Ten (10) years commencing on Ju |
|
| June 23, 2022 |
EX-1.1 2 xene-ex1163.htm EX-1.1 Exhibit 1.1 7,868,854 Shares 327,868 Pre-funded Warrants Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENT June 22, 2022 JEFFERIES LLC J.P. MORGAN SECURITIES LLC SVB SECURITIES LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o J.P. MORGAN SECURITIES LLC 383 Ma |
|
| June 23, 2022 |
7,868,854 Common Shares Pre-funded Warrants to Purchase 327,868 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-260010 PROSPECTUS SUPPLEMENT (To Prospectus dated October 4, 2021) 7,868,854 Common Shares Pre-funded Warrants to Purchase 327,868 Common Shares We are offering 7,868,854 of our common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 327,868 common shares in this offering. The purchase pr |
|
| June 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Xenon Pharmaceuticals Inc. |
|
| June 23, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 23, 2022 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [ ] (subject to adjustment) Original Issue Date: [ ], 2022 Warrant No. Xenon Pharmaceuticals Inc., a corporation continued under the federal laws of Canada (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| June 22, 2022 |
SUBJECT TO COMPLETION, DATED JUNE 22, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-260010 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| June 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 21, 2022 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial Plans to i |
|
| June 2, 2022 |
Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder. Exhibit 10.1 AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN XENON PHARMACEUTICALS INC. (as amended April 20, 2022) Article 1 PURPOSE 1.1 The purpose of this Plan is to promote the interests of Xenon Pharmaceuticals Inc. (the ?Company?) by: (a) furnishing certain directors, officers, employees of the Company and its subsidiaries or other persons as the Board of Directors may approve with greater i |
|
| June 2, 2022 |
As filed with the Securities and Exchange Commission on June 2, 2022 As filed with the Securities and Exchange Commission on June 2, 2022 Registration Statement No. |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 2, 2022 |
EX-FILING FEES 4 xene-exfilingfees8.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Xenon Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate |
|
| May 10, 2022 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update XEN1101 ?End of Phase 2? Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD Conference Call at 4: |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHA |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 28, 2022 |
DEF 14A 1 xene-def14a20220601.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 22, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 12)1 Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) |
|
| March 10, 2022 |
Exhibit 99.1 Craig Colosso Relationship Management American Stock Transfer & Trust Company, LLC Brooklyn, NY Office: 718.921.8337 E-mail: [email protected] March 10, 2022 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of t |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 1, 2022 |
Up to $250,000,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-260010 PROSPECTUS SUPPLEMENT (To prospectus dated October 4, 2021) Up to $250,000,000 Common Shares We have previously entered into an at-the-market equity offering sales agreement, dated August 6, 2020, as amended March 1, 2022, or the Sales Agreement, with Jefferies LLC, or Jefferies, and Stifel, Nicolaus & Company, Incorporated, or |
|
| March 1, 2022 |
EX-1.1 2 xene-ex1145.htm EX-1.1 Exhibit 1.1 AMENDMENT NO. 1 TO THE AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT March 1, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: This Amendment No. 1 to the At-The-Market Equity Offering Sales Agreement (this “Amendment”) is e |
|
| March 1, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Xenon Pharmaceuticals Inc. |
|
| March 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 1, 2022 |
CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 1, 2022 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 1, 2022 ? Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2021 and provided a corporate update. Mr. Ian Mortimer, Xe |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K .; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMA |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* (Name of Issuer) Xenon Pharmaceuticals Inc. (Title of Class of Securities) Common Shares, Without Par V |
|
| February 14, 2022 |
XENE / Xenon Pharmaceuticals Inc / DRIEHAUS CAPITAL MANAGEMENT LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Xenon Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 11)1 Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) |
|
| February 11, 2022 |
XENE / Xenon Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. |
|
| February 11, 2022 |
CUSIP No. 98420N105 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, without par value, of Xenon Pharmaceuticals Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securiti |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Xenon Pharmaceuticals, Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 12, 2022 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this ?Agreement?), is made as of January 11, 2022 (the ?Signing Date?), by and between Neurocrine Biosciences, Inc. (the ?Investor?), a Delaware corporation, and Xenon Pharmaceuticals Inc. (the ?Company?), a Canadian corporation. RECITALS WHEREAS, the Company and the Investor have entered into the Collaboration Agreement; and WHE |
|
| January 12, 2022 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone BURNABY, British Columbia, January 12, 2022 ? Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX |
|
| January 12, 2022 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 1, 2021 |
Exhibit 10.1 LEASE AGREEMENT THIS AGREEMENT MADE EFFECTIVE AS OF NOVEMBER 24, 2021 BETWEEN REDSTONE ENTERPRISES LTD. (the ?Landlord?) AND XENON PHARMACEUTICALS INC. (the ?Tenant?) REFERENCE The Landlord hereby demises unto the Tenant for and during a period of Ten (10) years commencing on July 1, 2022 and ending on June 30, 2032 (the ?Term?), that certain office space in the Building located at 36 |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2021 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, November 10, 2021 ? Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, |
|
| November 10, 2021 |
Employment Agreement, dated August 18, 2021, by and between the Company and Christopher Kenney. Exhibit 10.3 August 18, 2021 CONFIDENTIAL Via Electronic Mail Dr. Christopher Kenney Dear Christopher, Re: Offer of Employment We are pleased to offer you a position with Xenon Pharmaceuticals USA Inc. (the ?Company?), a wholly-owned subsidiary of Xenon Pharmaceuticals Inc. (the ?Parent?), as its Chief Medical Officer, beginning on August 23, 2021 (the ?Start Date?). Subject to Sections L through |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON |
|
| October 28, 2021 |
XENE / Xenon Pharmaceuticals Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Xenon Pharmaceuticals Inc. (Title of Class of Securities) Common Shares, Without Par Va |
|
| October 28, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| October 6, 2021 |
Exhibit 1.1 8,474,577 Shares 1,694,915 Pre-funded Warrants Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENT October 5, 2021 JEFFERIES LLC SVB LEERINK LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o SVB LEERINK LLC 255 California Street, 12th Floor San Francisco, California 94111 c/o STIFE |
|
| October 6, 2021 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to Rule 424(b)(5) Registration No. 333-260010 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Number of Securities to be Registered Maximum Offering Price Per Security Maximum Aggregate Offering Price Amount of Registration Fee Common shares, no par value per share 11,694,915 shares(2) $29.50 $344,999,992.50 $31,982 Pre-funded warrants to purchase |
|
| October 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 6, 2021 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [ ] (subject to adjustment) Original Issue Date: [ ], 2021 Warrant No. Xenon Pharmaceuticals Inc., a corporation continued under the federal laws of Canada (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| October 5, 2021 |
$250,000,000 Common Shares Pre-funded Warrants to Purchase Common Shares Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated October 5, 2021 Relating to Preliminary Prospectus Supplement Dated October 4, 2021 Registration Statement No. |
|
| October 4, 2021 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ?X-TOLE? Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Xenon to Host Conference Call and Live Webcast Today at 7:30 am Eastern T |
|
| October 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 4, 2021 |
As filed with the Securities and Exchange Commission on October 4, 2021 As filed with the Securities and Exchange Commission on October 4, 2021 Registration No. |
|
| October 4, 2021 |
SUBJECT TO COMPLETION, DATED OCTOBER 4, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-260010 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| September 8, 2021 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this ?Agreement?), is made as of September 8, 2021 (the ?Signing Date?), by and between Neurocrine Biosciences, Inc. (the ?Investor?), a Delaware corporation, and Xenon Pharmaceuticals Inc. (the ?Company?), a Canadian corporation. RECITALS WHEREAS, the Company and the Investor have entered into the Collaboration Agreement; and WH |
|
| September 8, 2021 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021 BURNABY, British Columbia, September 8, 2021 ? Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, to |
|
| September 8, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 23, 2021 |
EX-99.1 2 xene-ex9916.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer BURNABY, British Columbia, August 23, 2021 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, ef |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHAR |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2021 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update Topline Data from XEN1101 Phase 2b ?X-TOLE? Clinical Trial Anticipated Late September to Mid-October 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, August 11, 2021 ? Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, |
|
| August 11, 2021 |
Exhibit 10.1 August 6, 2021 Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 USA Attention: Pharma Partnering, Alliance Management Re: Collaborative Research and License Agreement between Xenon Pharmaceuticals Inc. (?Xenon?), on the one hand, and Genentech, Inc. (?GNE?) and F. Hoffmann-La Roche Ltd (?Roche? and, together with GNE, ?Genentech?), made as of December 22, 2011 (as amended to da |
|
| June 3, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHA |
|
| May 11, 2021 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Topline Data from XEN1101 Phase 2b ?X-TOLE? Clinical Trial Anticipated by End of Third Quarter of 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 11, 2021 ? Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today r |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2021 |
Exhibit 99.1 Craig Colosso Relationship Management American Stock Transfer & Trust Company, LLC Brooklyn, NY Office: 718.921.8337 E-mail: [email protected] March 12, 2021 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of t |
|
| March 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 10, 2021 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [ ] (subject to adjustment) Original Issue Date: [ ], 2021 Warrant No. Xenon Pharmaceuticals Inc., a corporation continued under the federal laws of Canada (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| March 10, 2021 |
4,324,325 Common Shares Pre-funded Warrants to Purchase 1,081,081 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-238896 PROSPECTUS SUPPLEMENT (To Prospectus dated June 12, 2020) 4,324,325 Common Shares Pre-funded Warrants to Purchase 1,081,081 Common Shares We are offering 4,324,325 of our common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 1,081,081 common shares in this offering. The purchase |
|
| March 10, 2021 |
Exhibit 1.1 4,324,325 Shares Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENT March 9, 2021 JEFFERIES LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 Seventh Avenue, 11th Floor New York, New York 10019 Ladies and Gentlemen: Introductory. Xenon |
|
| March 9, 2021 |
SUBJECT TO COMPLETION, DATED MARCH 9, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238896 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| March 1, 2021 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update XEN1101 Phase 2b “X-TOLE” Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in Third Quarter of 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 1, 2021 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today r |
|
| March 1, 2021 |
Exhibit 10.33 LEASE EXTENSION AND MODIFICATION AGREEMENT THIS AGREEMENT MADE EFFECTIVE AS OF OCTOBER 5, 2020 BETWEEN REDSTONE ENTERPRISES LTD. (?Landlord?) AND XENON PHARMACEUTICALS INC. (?Tenant?) WHEREAS: A. By a Lease dated in 2001 (the ?Original Lease?) between Discovery Parks Incorporated (the ?Original Landlord?) and Xenon Genetics Inc. (the ?Original Tenant?), the Original Landlord demised |
|
| March 1, 2021 |
Exhibit 10.4 SHARE OPTION AGREEMENT THIS AGREEMENT made on [] AMONG: Xenon Pharmaceuticals Inc., a company incorporated under the laws of Canada (the ?Company?) AND: [First Name, Last Name, Title] (the ?Optionee?) WHEREAS: A.The Optionee is a director, officer, employee or Consultant of the Company or of a subsidiary of the Company or of an Affiliate of the Company or a person otherwise approved b |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 1, 2021 |
.; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMA |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 10)1 Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
CUSIP No. 98420N105 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, without par value, of Xenon Pharmaceuticals Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securiti |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Xenon Pharmaceuticals, Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| February 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 14, 2021 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021 Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer at Annual Meeting of Shareholders in June 2021 Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021 Phas |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 (November 3, 2020) XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other J |
|
| January 14, 2021 |
Employment Agreement, dated January 13, 2021, by and between the Company and Ian Mortimer. Exhibit 10.2 January 13, 2021 Confidential Via Electronic Mail Ian Mortimer Dear Ian, Re: Employment Agreement We are pleased to offer you a promotion to the position President & Chief Executive Officer (“CEO”) with Xenon Pharmaceuticals Inc. (the “Company”), effective as of the Company’s 2021 annual meeting of shareholders expected to take place on or about June 4, 2021 (the “Effective Date”), on |
|
| January 14, 2021 |
Employment Agreement, dated January 13, 2021, by and between the Company and Sherry Aulin. Exhibit 10.4 January 13, 2021 Confidential Via Electronic Mail Sherry Aulin Dear Sherry, Re: Employment Agreement We are pleased to offer you a promotion to the position of Chief Financial Officer (“CFO”) with Xenon Pharmaceuticals Inc. (the “Company”), effective as of the Company’s 2021 annual meeting of shareholders expected to take place on or about June 4, 2021(the “Effective Date”), on the te |
|
| January 14, 2021 |
Employment Agreement, dated January 13, 2021, by and between the Company and Simon Pimstone. Exhibit 10.3 January 13, 2021 Confidential Via Electronic Mail Simon Pimstone Dear Simon, Re: Employment Agreement Further to your discussion with the Board to transition from the Chief Executive Officer role, we are pleased to offer you the position of Executive Chair of the Board of Directors, from the Company’s 2021 annual meeting of shareholders expected to take place on or about June 4, 2021 |
|
| January 14, 2021 |
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| November 5, 2020 |
Employment Agreement, dated July 17, 2020, by and between the Company and Christopher Von Seggern. Exhibit 10.3 July 14, 2020 CONFIDENTIAL Via Electronic Mail Christopher E. Von Seggern Dear Christopher, Re: Offer of Employment We are pleased to offer you a position with Xenon Pharmaceuticals USA Inc. (the "Company"), a wholly-owned subsidiary of Xenon Pharmaceuticals Inc. (the "Parent'), as its Chief Commercial Officer, beginning on August 17, 2020 (the "Appointment Date"). Subject to Sections |
|
| November 5, 2020 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Experienced Biotech Executive, Patrick Machado, Joins Xenon’s Board of Directors Conference Call at 4:30 pm ET Today BURNABY, British Columbia, November 5, 2020 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON |
|
| August 17, 2020 |
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer BURNABY, British Columbia, August 17, 2020 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced today the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately. In this newly created role, Dr. Von Seggern will r |
|
| August 17, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 6, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 6, 2020 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, August 6, 2020 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported its financ |
|
| August 6, 2020 |
Up to $100,000,000 Common Shares Xenon Pharmaceuticals Inc. Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-238896 PROSPECTUS SUPPLEMENT (To prospectus dated June 12, 2020) Up to $100,000,000 Common Shares Xenon Pharmaceuticals Inc. We have entered into an at-the-market equity offering sales agreement, dated August 6, 2020, or the Sales Agreement, with Jefferies LLC, or Jefferies, and Stifel, Nicolaus & Company, Incorporated, or Stifel, col |
|
| August 6, 2020 |
Exhibit 1.1 XENON PHARMACEUTICALS INC. Common Shares AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT August 6, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Xenon Pharmaceuticals Inc., a corporation continued under the federal laws of Canada (the “Company”), proposes |
|
| August 6, 2020 |
Quarterly Report - XENE-10Q-20200806-Q2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHAR |
|
| August 6, 2020 |
Exhibit 10.2 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [†]. AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This Amendment No. 1 (this “Amendment”), dated August 4, 2020 (the “Effective Date”), modifies that certain Asset Purchase Agreement (the “Ag |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 9)1 Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) |
|
| June 10, 2020 |
June 10, 2020 Re:Xenon Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-3 Registration Statement No. 333-238896 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Courtney Lindsay Dear Mr. Lindsay: In accordance with Rule 461 under the Securities Act of 1933, as amended, t |
|
| June 3, 2020 |
Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder. Exhibit 10.1 AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN XENON PHARMACEUTICALS INC. (as amended April 16, 2020) Article 1 PURPOSE 1.1 The purpose of this Plan is to promote the interests of Xenon Pharmaceuticals Inc. (the “Company”) by: (a) furnishing certain directors, officers, employees of the Company and its subsidiaries or other persons as the Board of Directors may approve with greater i |
|
| June 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 3, 2020 |
As filed with the Securities and Exchange Commission on June 3, 2020 Registration No. |
|
| June 3, 2020 |
As filed with the Securities and Exchange Commission on June 3, 2020 Registration No. |
|
| May 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q/A (Amendment No. 2) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| May 21, 2020 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs Additional FDA Feedback Supports Commencement of XEN496 Phase 3 Clinical Trial in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 21, 2020 – Xenon Pharmaceuticals Inc. (Nasd |
|
| May 21, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHA |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2020 |
EX-99.1 2 xene-ex99148.htm EX-99.1 Exhibit 99.1 Craig Colosso Relationship Management American Stock Transfer & Trust Company, LLC Brooklyn, NY Office: 718.921.8337 E-mail: [email protected] March 11, 2020 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting |
|
| March 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2020 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURTIIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Xenon Pharmaceuticals Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares, no par value per share. The general terms and provisions of our common shares are summarized below. This summary does |
|
| March 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEU |
|
| March 9, 2020 |
Exhibit 10.24 March 19, 2019 Confidential Via Electronic Mail Robin Sherrington Dear Robin, Re: Amended and Restated Employment Agreement We are pleased to offer you this Amended and Restated Employment Agreement which replaces and supersedes your earlier Employment Agreement. You will be credited for all purposes with your service to the Company back to your start date of May 1, 2001. As of March |
|
| March 9, 2020 |
Exhibit 10.25 March 20, 2019 Confidential Via Electronic Mail James Empfield Dear James, Re: Amended and Restated Employment Agreement We are pleased to offer you this Amended and Restated Employment Agreement which replaces and supersedes your earlier Offer of Employment (the “Prior Agreement”) dated January 1, 2017 with Xenon Pharmaceuticals USA Inc. (the “Company”), a wholly-owned subsidiary of |
|
| March 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2020 |
XENE / Xenon Pharmaceuticals Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on March 9, 2020 Registration No. |
|
| March 9, 2020 |
Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update Xenon’s Robust Neurology Pipeline of Proprietary and Partnered Programs Advances with Multiple Important Milestone Opportunities Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 9, 2020 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biop |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 8)1 Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 98420N105 (CUSIP Number) |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the shares of Common Stock of Xenon Pharmaceuticals Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) u |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) * Xenon Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 12, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Xenon Pharmaceuticals Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 98420N105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 23, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 23, 2020 |
Exhibit 1.1 3,750,000 Shares Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENT January 22, 2020 JEFFERIES LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 Seventh Avenue, 11th Floor New York, New York 10019 c/o GUGGENHE |
|
| January 23, 2020 |
3,750,000 Shares Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-233056 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 15, 2019) 3,750,000 Shares Common Shares We are offering 3,750,000 of our common shares. Our common shares are listed on the Nasdaq Global Market under the symbol “XENE.” The last reported sale price of our common shares on the Nasdaq Global Market on January 22, 2020 was $16.83 per share |
|
| January 22, 2020 |
SUBJECT TO COMPLETION, DATED JANUARY 22, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233056 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2020 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 11, 2019 |
XENE / Xenon Pharmaceuticals Inc. / Neurocrine Biosciences Inc - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* XENON PHARMACEUTICALS INC. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 98420N105 (CUSIP Number) Kevin C. Gorman, Ph.D. Chief Executive Officer Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, CA 92130 (858) |
|
| December 2, 2019 |
Exhibit 99.1 Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milest |
|
| December 2, 2019 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [†]. License and Collaboration Agreement by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. Dated as of December 2, 2019 Table of Contents Page ARTICLE 1 DEFINITIONS |
|
| December 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2019 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter) Canada 001-36687 98-0661854 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 2, 2019 |
Exhibit 10.2 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”), is made as of December 2, 2019 (the “Signing Date”), by and between Neurocrine Biosciences, Inc. (the “Investor”), a Delaware corporation, and Xenon Pharmaceuticals Inc. (the “Company”), a Canadian corporation. RECITALS WHEREAS, the Company and the Investor have entered into the Collaboration Agreement; and WHE |
